Research Triangle Park, NC, December 20, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, following a pre-submission meeting with the oncology division of the U.S. Food and Drug Administration…Original Article
Fennec Pharmaceuticals Initiates Rolling New Drug Application to FDA for Pedmark
